

## Tropism, Mapping, Modeling, and Therapy using Canine Adenovirus Vectors in the CNS

Iria G. Dopeso Reyes $^{1*}$ , Mathieu Wolff $^{2*}$ , Melissa R. Andrews $^{3*}$ , Eric J. Kremer $^{1*}$ 

<sup>1</sup>Institut de Génétique Moléculaire de Montpellier, Université de Montpellier, CNRS, Montpellier, France, France, <sup>2</sup>Centre National de la Recherche Scientifique, INCIA, Unité Mixte de Recherche 5287, Université de Bordeaux, France, <sup>3</sup>School of Biological Sciences, University of Southampton, United Kingdom

Submitted to Journal: Frontiers in Molecular Neuroscience

Article type: Editorial Article

Manuscript ID: 636476

Received on: 01 Dec 2020

Frontiers website link: www.frontiersin.org



### Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

### Author contribution statement

All authors contributed to the writing and agreed on the final submission.

### Keywords

CAV-2, Neural circuit tracing, gene transfer, Parkinson's disease, Coxsackievirus adenovirus receptor, retrograde transport, DREADDs, optogenetics, LRRK2, Locus coeruleus (LC), Rodents, nonhuman primates

Contribution to the field

NA

# Tropism, Mapping, Modeling, and Therapy using Canine Adenovirus Vectors in the CNS

This Frontiers in Molecular Neuroscience Research Topic addresses tropism, mapping, modeling, and therapy using canine adenovirus (CAV-2) vectors in the CNS. Genetic modification of cells in the brain or spinal cord, whether to understand brain structure/function or for therapeutic reasons, has undergone a revolution in the last decade. The current collection of viral vectors gives scientists a multifunctional kit to target neurons in many brain structures. Approximately 20 years ago, we demonstrated the capacity of CAV-2 vectors to preferentially infect neurons and their high retrograde transport capacity (Soudais et al., 2001). Richard Palmiter's lab was one of the first to take advantage of CAV-2 vector retrograde transport and addressed the physiological functions of the substantia nigra (Hnasko et al. 2005; Hnasko et al. 2006). The evolution of gene transfer vectors for the CNS has not abated. In this Research Topic, our goal was to provide a readily accessible collection of reviews and primary studies that epitomize the advantages and drawbacks of CAV-2 vectors in the mammalian CNS.

For some neuroscientists, the idiosyncrasies of each vector platform are confusing because the best choice will depend upon their unique question(s). The first question is likely "Which vector is best to infect neurons?" While adenovirus vectors can use numerous cell surface molecules to eventually infect cells (Arnberg, 2012), most of the >200 types have not been tested in the CNS. The distinction with CAV-2 is that for all intents and purposes it depends on the cell adhesion molecule called "coxsackievirus and adenovirus receptor" (CAR) (Soudais et al., 2001, Salinas et al., 2009). Fortunately, CAR is highly conserved, and all mammals appear to express CAR on neurons in the brain parenchyma (Whebi et al., 2020). Inasmuch, CAV-2 vectors have been used efficiently in rodents (Morceau et al., 2019; Martel et al., 2020; Cerpa et al., 2020, Kakava-Georgiadou et al., 2019), dogs (Cubizolle et al., 2014) and primates (di Caudo et al., 2020, reviewed by Lasbleiz et al., 2019). Not only are CAV-2 vectors efficient but they also appear to drive highly selective expression, which is sometimes a concern with AAV-based conditional constructs with leakage of gene expression, prompting the need to either work out the optimal virus titration (Morceau et al., 2019) or to rely on CAV-2 vectors and transgenic lines (Cerpa et al., 2019).

The second question is likely to be — "Which vector has the capacity to harbor my expression cassette of interest?" E1/E3-deleted CAV-2 vectors have a cloning capacity > 7 kbp, while helper-dependent CAV-2 vectors (HD-CAV2) have a cloning capacity up to 36 kbp (del Rio et al., 2019). This is clearly one characteristic that sets CAV-2 vectors apart from others (except HSV vectors, which have a theoretical capacity of 150 kb). By exploiting this characteristic di Caudo et al. (2020) and Mestre-Francés et al. (2019) created vectors harboring a leucine-rich repeat kinase 2 (LRRK2) cassette containing a point mutation (G2019S) to produce genetic NHP models of Parkinson disease (reviewed by Lasbleiz et al., 2019).

The third issue typically concerns the type of neuron that needs to be targeted. CAR is present mainly but not exclusively in axons (Whebi et al., 2020) of different neuronal populations (reviewed by Lavoie and Liu, 2019), allowing one to target different types of neurons in different areas of the CNS in rodents and the peripheral nervous system in primates (Bohlen et al., 2019). If one combines the presence of CAR and a specific promoter, transgene expression can be targeted to cholinergic interneurons (Martel et al., 2020) or neurons in the locus coeruleus (Hirschberg et al., 2017; Xiang et al., 2019; Hayat et al., 2020). Furthermore, Lavoie and Liu (2019) compiled a list of possible neuronal subtypes (glutamatergic, dopaminergic, catecholaminergic, serotoninergic, oxytonic and GABAergic) that have been effectively transduced by CAV-2 vectors and they also point out that the lack of infection of some projecting neuron types is possible.

The ability of the neuronal presynapse to endocytose CAV-2 particles and confuse them for cargo destined for transport to the soma (retrograde transport) provided neuroscientists with one of the first efficient vectors to address neuronal circuitry. Trying to understand how the 100 billion neurons, via the trillions of synapses, in a human brain interact, and how a given subset influences behavior may never be understood. However, this daunting task has not stopped many from trying to use less complex systems to provide a rough blueprint as a starting point. In addition to circuitry, the advent of opto- and chemogenetics now allows one to address the function of selected neuronal populations (Cerpa et al., 2020).

Finally, CAV-2 vectors (both E1/E3-deleted and HD) are also capable of long-term expression, (del Rio et al., 2019; Hirschberg et al. 2017). The study of the transcriptional pathways affected by HD-CAV2 demonstrated there was a modest modulation of genes involved in the immune response, intracellular trafficking, and transcriptional regulation (reviewed by del Rio et al., 2019).

In summary, the future of neuron-targeted gene transfer has many options – and in particular CAV-2 vectors have many favorable characteristics.

Iria Gonzalez-Dopeso Reyes<sup>1</sup>, Mathieu Wolff<sup>2</sup>, Melissa R Andrews<sup>3</sup>, Eric J Kremer<sup>1</sup>

<sup>1</sup>Institut de Génétique Moléculaire de Montpellier, Université de Montpellier, CNRS, Montpellier, France

<sup>2</sup>Centre National de la Recherche Scientifique, INCIA, Unité Mixte de Recherche 5287, Université de Bordeaux, Bordeaux, France

<sup>3</sup>School of Biological Sciences, University of Southampton, Southampton, SO17 1BJ, UK

#### References

Arnberg N. (2012). Adenovirus receptors: Implications for targeting of viral vectors. Trends Pharmacol. Sci. 33, 442–448. doi: 10.1016/j.tips.2012.04.005

Cubizolle A, Serratrice N, Skander N, Colle MA, Ibanes S, Gennetier A, et al. (2014). Corrective GUSB transfer to the canine mucopolysaccharidosis VII brain. Mol. Ther. 22, 762–773. doi: 10.1038/mt.2013.283

Hayat H, Regev N, Matosevich N, Sales A, Paredes-Rodriguez E, Krom AJ, Bergman L, Li Y, Lavigne M, Kremer EJ, Yizhar O, Pickering AE, Nir Y. (2020). Locus coeruleus norepinephrine activity mediates sensory-evoked awakenings from sleep. Sci Adv. 2020 Apr 8;6(15):eaaz4232. doi: 10.1126/sciadv.aaz4232

Hirschberg S, Li Y, Randall A, Kremer EJ, Pickering AE. (2017). Functional dichotomy in spinal- vs prefrontal-projecting locus coeruleus modules splits descending noradrenergic analgesia from ascending aversion and anxiety in rats. Elife. 2017 Oct 13;6:e29808. doi: 10.7554/eLife.29808.

Hnasko TS, Perez FA, Scouras AD, Stoll EA, Gale SD., Luquet S, et al. (2006). Cre recombinase-mediated restoration of nigrostriatal dopamine in dopamine-deficient mice reverses hypophagia and bradykinesia. Proc. Natl. Acad. Sci. U.S.A. 103, 8858–8863. doi: 10.1073/pnas.0603081103

Hnasko TS, Sotak BN, and Palmiter RD. (2005). Morphine reward in dopamine-deficient mice. Nature 438, 854–857

Mestre-Francés N, Serratrice N, Gennetier A, Devau G, Cobo S, Trouche S, et al. (2019). Exogenous LRRK2G2019S induces parkinsonian-like pathology in a nonhuman primate. JCI Insight 3:98202. doi: 10.1172/jci.insight.98202

Salinas S, Bilsland LG, Henaff D, Weston AE, Keriel A, Schiavo G, et al. (2009). CAR-associated vesicular transport of an adenovirus in motor neuron axons. PLoS Pathog. 5:e1000442. doi: 10.1371/journal.ppat.1000442

Soudais C, Laplace-Builhe C, Kissa K, and Kremer EJ. (2001). Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo. FASEB J. 15, 2283–2285. doi: 10.1096/fj.01-0321fje

Xiang L, Harel A, Gao H, Pickering AE, Sara SJ, Wiener SI. (2019). Behavioral correlates of activity of optogenetically identified locus coeruleus noradrenergic neurons in rats performing T-maze tasks. Sci Rep. 2019 Feb 4;9(1):1361 doi: 10.1038/s41598-018-37227-w.

